Literature DB >> 9010371

Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies.

H C Barry1, M H Ebell, J Hickner.   

Abstract

BACKGROUND: The purpose of this study was to determine the most cost-effective strategy for managing suspected urinary tract infections in otherwise healthy adult women presenting to their primary care physician with dysuria and no symptoms or signs of pyelonephritis. Several office-based management strategies are considered: empiric therapy, use of dipstick analysis, use of complete urinalysis, and several strategies using office or laboratory cultures.
METHODS: We constructed a decision tree using model probabilities obtained from the literature. Where published probabilities were unavailable, we used extensive sensitivity analyses. Utilities were obtained from the Index of Well-Being. We obtained costs by surveying hospitals, physicians, and pharmacies.
RESULTS: The most cost-effective strategy is to treat empirically ($71.52 per quality-adjusted life month, QALM). When the cost of antibiotics exceeds $74.50 or if the prior probability of having a UTI is under 0.30, then treatment guided by the results of a complete urinalysis is preferred. While it was the preferred strategy, other strategies (complete urinalysis, culture and treat, and dipstick testing only) were associated with greater utility. The marginal cost-effectiveness of these strategies compared with empiric therapy ranged from $2964 to $48,460 per additional QALM.
CONCLUSIONS: The preferred strategy of empiric therapy is robust over a wide range of sensitivity analyses. While empiric therapy is associated with the best cost-utility ratio, doing a culture yields the greatest utility at greater incremental cost per QALM. Many primary care physicians already treat UTIs empirically with antibiotics. This study confirms that empiric therapy, while frowned upon by some, is a cost-effective strategy. Other strategies may be considered, but at greater marginal cost. Ultimately these findings need to be confirmed in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010371

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  38 in total

1.  New-variant Creutzfeldt-Jacob disease.

Authors:  G Smith; R Charlton
Journal:  Br J Gen Pract       Date:  2000-08       Impact factor: 5.386

2.  Empirical treatment of uncomplicated cystitis.

Authors:  A Baerheim
Journal:  BMJ       Date:  2001-11-24

3.  Toward a simple diagnostic index for acute uncomplicated urinary tract infections.

Authors:  Bart J Knottnerus; Suzanne E Geerlings; Eric P Moll van Charante; Gerben Ter Riet
Journal:  Ann Fam Med       Date:  2013 Sep-Oct       Impact factor: 5.166

4.  Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.

Authors:  James A McKinnell; Nicholas S Stollenwerk; Chin W Jung; Loren G Miller
Journal:  Mayo Clin Proc       Date:  2011-05-16       Impact factor: 7.616

5.  Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.

Authors:  Jonathan Karnon; Keith Tolley; Joao Vieira; David Chandiwana
Journal:  Clin Drug Investig       Date:  2012-12       Impact factor: 2.859

Review 6.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

7.  [The disturbing development of resistance in urinary tract infections].

Authors:  C Hampel; R Gillitzer; S Pahernik; J W Thüroff
Journal:  Urologe A       Date:  2002-12-20       Impact factor: 0.639

8.  Cost effectiveness of management strategies for urinary tract infections: results from randomised controlled trial.

Authors:  David Turner; Paul Little; James Raftery; Sheila Turner; Helen Smith; Kate Rumsby; Mark Mullee
Journal:  BMJ       Date:  2010-02-05

9.  All dysuria is local. A cost-effectiveness model for designing site-specific management algorithms.

Authors:  Michael B Rothberg; John B Wong
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 5.128

Review 10.  Contemporary management of uncomplicated urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.